Person
José Baselga
Oncologist; chief medical officer of Memorial Sloan Kettering Cancer Center until September 2018, later head of oncology research and development at AstraZeneca. Died 21 March 2021.
- worked at Memorial Sloan Kettering Cancer Center (chief medical officer and physician-in-chief) 2013 – 13 Sep 2018
He died on 21 March 2021, OncLive reported, at 61. The company said he was then executive vice president of oncology research and development at AstraZeneca.
Connections 3
worked at
- Memorial Sloan Kettering Cancer Center 2013 – 13 Sep 2018 chief medical officer and physician-in-chief Scholarship & press 12
- Massachusetts General Hospital chief of hematology and oncology Scholarship & press 1
involved in
- Baselga's unreported industry ties, 2018 the doctor whose disclosures were examined; he said they were unintentional Scholarship & press 13
Timeline 1 date
- 2013 – 13 Sep 2018 José Baselga worked at Memorial Sloan Kettering Cancer Center
Proof 3 sources
-
Top Official at Memorial Sloan Kettering Resigns After Failing to Disclose Industry Ties, ProPublica and The New York Times, 13 Sep 2018.
Scholarship & press
Dr. José Baselga, the chief medical officer of Memorial Sloan Kettering Cancer Center, resigned on Thursday amid reports that he had failed to disclose millions of dollars in payments from health care companies in dozens of research articles.
He came to Memorial Sloan Kettering in 2013
He came to Memorial Sloan Kettering in 2013 after serving as chief of hematology and oncology at Massachusetts General Hospital in Boston.
All told, ProPublica and The Times found that Baselga had failed to report any industry ties in 60 percent of the nearly 180 papers he had published since 2013.
-
José Baselga, Scientific Leader in Oncology, Dies at 61, OncLive, 21 Mar 2021.
Scholarship & press
passed away on Sunday, March 21, 2021 at the age of 61
-
Top Cancer Doctor Resigns as Editor of Medical Journal, ProPublica and The New York Times, 19 Dec 2018.
Scholarship & press
The AACR, which he formerly led as president, concluded that his omissions were inadvertent and said it would allow Baselga to continue publishing in its journals.
Page history 1 change
- Add 55 stories, each checked against its sources96e92fe6
Something wrong or missing? Tell us, with a source, or edit this page.